New drug combo tested for tough cancers
NCT ID NCT06108479
First seen Mar 28, 2026 · Last updated Apr 29, 2026 · Updated 3 times
Summary
This early-phase study tested a new drug called DF6215, alone or with another drug (pembrolizumab), in 35 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find the safest dose and check for side effects. The study is complete, but results are not yet available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Marseille - Hôpital de la Timone
Marseille, 13005, France
-
Cancer Research SA (CRSA)
Adelaide, South Australia, 5000, Australia
-
Centre Georges François Leclerc
Dijon, 21000, France
-
Centre Hospitalier Universitaire de Bordeaux
Bordeaux, 33075, France
-
Centre Hospitalier Universitaire de Poitiers
Poitiers, 86000, France
-
Hôpital Lyon-Sud
Pierre-Bénite, 69495, France
-
Institut Bergonié
Bordeaux, 33000, France
-
Institut Curie
Paris, 75005, France
-
Institut Paoli-Calmettes
Marseille, 13009, France
-
Institut Universitaire du Cancer de Toulouse Oncopole
Toulouse, 31100, France
-
Institut de Cancérologie de l'Ouest - Saint-Herblain - Site René Gauducheau
Saint-Herblain, 44805, France
-
Lifespan - Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
NYU Langone Health
New York, New York, 10016, United States
-
Peninsula and South East Oncology Medical (PASO)
Frankston, Victoria, 3199, Australia
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
Sarcoma Oncology Center
Santa Monica, California, 90403, United States
-
Tampa General Hospital
Tampa, Florida, 33606, United States
-
The Angeles Clinic and Research Institute - West Los Angeles Office
Los Angeles, California, 90025, United States
-
University of California Irvine Medical Center
Orange, California, 92868, United States
-
University of California San Diego Moores Cancer Center
San Diego, California, 92093, United States
Conditions
Explore the condition pages connected to this study.